Human ST3GAL4 Protein 4189

$450.00 – $1,500.00

Summary

Expression: HEK293
Pure: Yes (SDS-PAGE)
Amino Acid Range: Glu41-Phe333

SKU: 4189parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	Q11206
express system	HEK293
product tag	N-HA, C-His
purity	> 95% as determined by Tris-Bis PAGE
background	ST3GAL4 gene expression is altered in different cancer types, including cervical cancer. Several mRNA transcripts have been reported for this gene. ST3GAL4 encodes for β‑galactosidase α‑2, 3‑sialyltransferase 4, involved in the biosynthesis of the tumour antigens sLe(x) and sulfo‑sLe(x).
molecular weight	The protein has a predicted MW of 35.4 kDa. Due to glycosylation, the protein migrates to 48-53 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Human ST3GAL4 Protein 4189

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
ST3GAL4 gene expression is altered in different cancer types, including cervical cancer. Several mRNA transcripts have been reported for this gene. ST3GAL4 encodes for β-galactosidase α-2,3-sialyltransferase 4, involved in the biosynthesis of the tumour antigens sLe(x) and sulfo-sLe(x).
Protein names CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (Alpha 2,3-ST 4) (Beta-galactoside alpha-2,3-sialyltransferase 4) (EC 2.4.3.2) (EC 2.4.3.4) (Alpha 2,3-sialyltransferase IV) (Gal-NAc6S) (Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase) (Gal-beta-1,4-GlcNAc-alpha-2,3-sialyltransferase) (N-acetyllactosaminide alpha-2,3-sialyltransferase) (EC 2.4.3.6) (SAT-3) (ST-4) (ST3Gal IV) (ST3GalIV) (ST3GalA.2) (STZ) (Sialyltransferase 4C) (SIAT4-C)
Gene names ST3GAL4,ST3GAL4 CGS23 NANTA3 SIAT4C STZ
Protein family Glycosyltransferase 29 family
Mass 38045Da
Function FUNCTION: A beta-galactoside alpha2-3 sialyltransferase involved in terminal sialylation of glycoproteins and glycolipids (PubMed:8288606, PubMed:8611500). Catalyzes the transfer of sialic acid (N-acetyl-neuraminic acid; Neu5Ac) from the nucleotide sugar donor CMP-Neu5Ac onto acceptor Galbeta-(1->3)-GalNAc- and Galbeta-(1->4)-GlcNAc-terminated glycoconjugates through an alpha2-3 linkage (PubMed:8288606, PubMed:8611500). Plays a major role in hemostasis. Responsible for sialylation of plasma VWF/von Willebrand factor, preventing its recognition by asialoglycoprotein receptors (ASGPR) and subsequent clearance. Regulates ASGPR-mediated clearance of platelets (By similarity). Participates in the biosynthesis of the sialyl Lewis X epitopes, both on O- and N-glycans, which are recognized by SELE/E-selectin, SELP/P-selectin and SELL/L-selectin. Essential for selectin-mediated rolling and adhesion of leukocytes during extravasation (PubMed:25498912). Contributes to adhesion and transendothelial migration of neutrophils likely through terminal sialylation of CXCR2 (By similarity). In glycosphingolipid biosynthesis, sialylates GM1 and GA1 gangliosides to form GD1a and GM1b, respectively (PubMed:8288606). Metabolizes brain c-series ganglioside GT1c forming GQ1c (By similarity). Synthesizes ganglioside LM1 (IV3Neu5Ac-nLc4Cer), a major structural component of peripheral nerve myelin (PubMed:8611500). {ECO:0000250\|UniProtKB:P61131, ECO:0000250\|UniProtKB:Q91Y74, ECO:0000269\|PubMed:25498912, ECO:0000269\|PubMed:8288606, ECO:0000269\|PubMed:8611500}.
Catalytic activity CATALYTIC ACTIVITY: Reaction=a beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl derivative + CMP-N-acetyl-beta-neuraminate = an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl derivative + CMP + H(+); Xref=Rhea:RHEA:52380, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:136588, ChEBI:CHEBI:136589; EC=2.4.3.2; Evidence={ECO:0000269\|PubMed:8288606}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52381; Evidence={ECO:0000305\|PubMed:8288606}; CATALYTIC ACTIVITY: Reaction=a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative + CMP-N-acetyl-beta-neuraminate = an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative + CMP + H(+); Xref=Rhea:RHEA:21616, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:133470, ChEBI:CHEBI:139596; EC=2.4.3.4; Evidence={ECO:0000269\|PubMed:8288606}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21617; Evidence={ECO:0000305\|PubMed:8288606}; CATALYTIC ACTIVITY: Reaction=a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + CMP-N-acetyl-beta-neuraminate = an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + CMP + H(+); Xref=Rhea:RHEA:52316, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:133507, ChEBI:CHEBI:136545; EC=2.4.3.6; Evidence={ECO:0000269\|PubMed:8288606, ECO:0000269\|PubMed:8611500}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52317; Evidence={ECO:0000305\|PubMed:8288606, ECO:0000305\|PubMed:8611500}; CATALYTIC ACTIVITY: Reaction=a ganglioside GM1 (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GD1a (d18:1(4E)) + CMP + H(+); Xref=Rhea:RHEA:18021, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:77709, ChEBI:CHEBI:78445; EC=2.4.3.2; Evidence={ECO:0000269\|PubMed:8288606}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18022; Evidence={ECO:0000305\|PubMed:8288606}; CATALYTIC ACTIVITY: Reaction=a ganglioside GA1 (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GM1b (d18:1(4E)) + CMP + H(+); Xref=Rhea:RHEA:47560, ChEBI:CHEBI:15378, ChEBI:CHEBI:27938, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:78568; Evidence={ECO:0000269\|PubMed:8288606}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47561; Evidence={ECO:0000305\|PubMed:8288606}; CATALYTIC ACTIVITY: Reaction=a ganglioside GT1c (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GQ1c (d18:1(4E)) + CMP + H(+); Xref=Rhea:RHEA:47588, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:87789, ChEBI:CHEBI:87791; Evidence={ECO:0000250\|UniProtKB:P61131}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47589; Evidence={ECO:0000250\|UniProtKB:P61131}; CATALYTIC ACTIVITY: Reaction=a neolactoside nLc4Cer + CMP-N-acetyl-beta-neuraminate = a neolactoside IV(3)-alpha-NeuAc-nLc4Cer + CMP + H(+); Xref=Rhea:RHEA:65432, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:90376, ChEBI:CHEBI:90390; Evidence={ECO:0000269\|PubMed:8611500}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:65433; Evidence={ECO:0000305\|PubMed:8611500}; CATALYTIC ACTIVITY: Reaction=a neolactoside nLc4Cer(d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a neolactoside IV(3)-alpha-NeuAc-nLc4Cer(d18:1(4E)) + CMP + H(+); Xref=Rhea:RHEA:18913, ChEBI:CHEBI:15378, ChEBI:CHEBI:17006, ChEBI:CHEBI:57812, ChEBI:CHEBI:58665, ChEBI:CHEBI:60377; EC=2.4.3.6; Evidence={ECO:0000305\|PubMed:8611500}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18914; Evidence={ECO:0000305\|PubMed:8611500};
Pathway PATHWAY: Protein modification; protein glycosylation. {ECO:0000305\|PubMed:8288606}.; PATHWAY: Glycolipid biosynthesis. {ECO:0000305\|PubMed:8288606}.
Subellular location SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Secreted. Note=Membrane-bound form in trans cisternae of Golgi. Secreted into the body fluid.
Tissues TISSUE SPECIFICITY: Highly expressed in adult placenta, heart and kidney. {ECO:0000269\|PubMed:8288606}.
Post-translational modification PTM: The soluble form derives from the membrane form by proteolytic processing.
Target Relevance information above includes information from UniProt accession: Q11206
The UniProt Consortium

Data

Human ST3GAL4 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.